Rasonque (daraxonrasib), developed by Revolution Medicines, works by blocking activated RAS protein — a key driver of tumor growth in most patients with pancreatic adenocarcinoma, the most common and most aggressive form of pancreatic cancer.
The drug, taken as a once‑daily tablet, is viewed as a breakthrough in the treatment of this notoriously difficult‑to‑treat disease.
BREAKING